Hodgkin's Lymphoma after Initiation of Antiretroviral Therapy in a Patient from India.
Vinay Kumar Konan, S T Kavya, Mohan C Nagchand, Bhushan C Shetty
Author Information
Vinay Kumar Konan: Junior Resident, Department of Medicine, BMCRI, RGUHS, Bengaluru, India.
S T Kavya: Professor, Department of Medicine, BMCRI, RGUHS, Bengaluru, India.
Mohan C Nagchand: Assistant Professor, Department of Medicine, SABVMRI, RGUHS, Bengaluru, India.
Bhushan C Shetty: Assistant Professor, Department of Nephrology, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India.
SUMMARY: Malignancies in human immunodeficiency virus (HIV) positive individuals have a larger role in morbidity and mortality. Appropriate clinical acumen is required for a clinician to anticipate the occurrence of lymphoma after starting antiretroviral therapy, especially in patients with CD4 <100 cells/mm3. Here is a 30-year-old man with weight loss and appetite, found to be retroviral disease positive status with low CD 4 counts. He was started on antiretroviral treatment, and following that, he developed Hodgkin's lymphoma of mixed cellularity. He is planned for an ABVD regimen and received one cycle of the same without any complications. To our knowledge, we are reporting the first case of an HIV patient with a mixed cellularity form of classical Hodgkin's lymphoma from India.
Engels EA, Pfeiffer RM, Goedert JJ, Virgo P, McNeel TS, Scoppa SM, et al. Trends in cancer risk among people with AIDS in the United States, 1980-2002. AIDS 2006;20:1645–54.
Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 2003;21:3447–53.
